









PROGRAM	Indications	Discovery	Preclinical	Phase 1	Phase 2	Phase 3	Next Milestone
<b>FRTX-02</b> Oral DYRK1A Inhibitor	<b>Autoimmune Diseases</b> <ul style="list-style-type: none"> <li>• Atopic Dermatitis</li> <li>• Rheumatoid Arthritis</li> <li>• Type 1 Diabetes</li> <li>• Others</li> </ul>						Phase 1 SAD/MAD Topline Results: Early 2023
<b>FRTX-10</b> Oral STING Inhibitor	<b>Autoinflammatory Diseases</b> <ul style="list-style-type: none"> <li>• Systemic Lupus Erythematosus</li> <li>• NASH</li> <li>• Dermatomyositis</li> </ul>						Preclinical Development
<b>Next-Generation Kinase Inhibitors</b> Oral DYRK1A, LRRK2, TTK, and CLK Inhibitors	<b>Autoimmune, Neuroinflammatory, and Other Diseases</b>						Experimental Characterization
<b>FRTX-03</b> Topical DYRK1A Inhibitor	<b>Autoimmune Dermatology</b> <ul style="list-style-type: none"> <li>• Atopic Dermatitis</li> <li>• Psoriasis</li> <li>• Others</li> </ul>						Formulation Development